Drug intelligence / Profile preview

picataxel

Development stage: Phase 1
Lead developer: SPARC
Modality: Small Molecules
Administration: Intravenous

Overview

Picataxel (SPARC1023) is a novel taxane derivative developed by Sun Pharma Advanced Research Company Limited (SPARC) for the treatment of advanced solid tumors. As a member of the taxane class, picataxel acts as a microtubule-stabilizing agent; it binds to tubulin, promoting the assembly of microtubules and inhibiting their disassembly. This stabilization interferes with the normal dynamics of the mitotic spindle, leading to cell cycle arrest at the G2/M phase and subsequent programmed cell death (apoptosis). SPARC1023 has been evaluated in Phase 1 clinical trials as both a single agent and in combination with carboplatin to determine its safety, tolerability, and preliminary efficacy in patients with refractory or advanced malignancies.

Other names: Picataxel

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on picataxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on picataxel.

Explore the full profile